Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vatreptacog alfa
- Development stage
- Discontinued
- Lead developer
- Novo Nordisk
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Vatreptacog alfa is a genetically engineered, activated recombinant human factor VIIa (rFVIIa) analog developed to improve the treatment of bleeding episodes in hemophilia patients with inhibitors. It contains three amino acid substitutions (V158D, E296V, M298Q) compared to native rFVIIa, resulting in enhanced tissue factor-independent activation of factor X and increased hemostatic activity. The drug was produced using CHO cell lines and was investigated for use in hemophilia A and B patients with inhibitors. Clinical trials demonstrated rapid and sustained resolution of bleeding episodes; however, development was discontinued after phase 3 due to the emergence of anti-drug antibodies in some patients[2][4][5][6].
- Other names
- vatreptacog alfa (activated)recombinant factor VIIa analog with mutations V158D/E296V/M298Q
02
Targets
F10 (Factor Xa)HLA-DR (Human leukocyte antigen DR)EPCR (Endothelial protein C receptor)
Beyond the preview
Go deeper on vatreptacog alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vatreptacog alfa.